Skip to main content
OpenTrials
Completed

NCT Number: NCT00469482

The SOMNUS Study: Sedative Optimization Via Monitoring Neurological Status

A combined strategy of Richmond Agitation and Sedation Scale (RASS) clinical targeting plus bispectral index (BIS) guided sedation in mechanically ventilated, critically ill patients will decrease time on mechanical ventilation, decrease the duration of intensive care unit (ICU) delirium and coma, and will improve subacute neurocognitive function when compared to sedation guided by RASS targeting alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States

About this study

Sedatives and analgesics are used to maintain comfort in almost all mechanically ventilated patients. Unfortunately, these medications also have many deleterious effects. Sedatives increase time on mechanical ventilation, have adverse hemodynamic effects, disturb sleep architecture, and have been determined to be an independent risk factor for ICU delirium. Delirium is an independent determinant of longer hospital stay, higher costs, and higher mortality, and the presence of delirium is highly predictive of long-term neurocognitive deficits. In consideration of these facts, better methods are needed to guide sedation, avoid oversedation, and possibly reduce delirium.

Current guidelines recommend titration of sedation to a goal level based on bedside evaluation using a validated assessment tool, e.g. the Richmond Agitation and Sedation Scale. These assessment tools, however, are underused and many ICU patients are oversedated with well described consequences. A practical method by which to determine where a patient lies may prove beneficial in optimizing our delivery of sedatives and improving patient outcomes.

While conventional EEG monitoring is not practical in the ICU, bispectral index (BIS) monitoring may be easily used in this clinical setting. BIS monitoring may provide a means to assess sedation level in unresponsive or paralyzed ICU patients and to decrease the total amount of sedatives/analgesics administered. Additional benefits of a combined clinical sedation scale and BIS-monitoring approach could include a decreased incidence and/or duration of delirium as well as a decreased incidence and severity of ICU-associated prolonged neurocognitive deficits.

The specific aims of this study are as follows:

Aim 1: To determine if sedative and analgesic medication delivery guided by clinical sedation scales and BIS monitor parameters of over-sedation will decrease time on mechanical ventilation.

Aim 2: To determine if sedative and analgesic medication delivery guided by clinical sedation scales and BIS monitor parameters of over-sedation will decrease the duration of delirium and coma when compared to the use of clinical sedations scales alone.

Aim 3: To determine if sedative and analgesic medication delivery guided by clinical sedation scales and BIS monitor parameters of over-sedation will decrease the incidence and severity of subacute cognitive impairment when compared to the use of clinical sedation scales alone.

Aim 4: To characterize polysomnography findings in critically ill patients at various BIS levels.

Aim 5: To determine if poor sleep quality is a factor in post critical illness neurocognitive dysfunction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female adult patients admitted to the ICU for critical illnesses requiring mechanical ventilation with expectation of being mechanically ventilated for greater than 24 hours. Subjects must have an actual or a target RASS of -3 or deeper with 48 hours of initiation of mechanical ventilation.

Exclusion criteria

  • Subjects who are less than 18 years old.
  • Inability to obtain informed consent from the patient or his/her surrogate.
  • Subjects admitted with alcohol or drug overdoses, suicide attempts, or alcohol/delirium with tremors.
  • Subjects with documented moderate to severe dementia.
  • Subjects with anoxic brain injuries, strokes, neurotrauma, or neuromuscular disorders such as myasthenia gravis or Guillain Barre syndrome.
  • Subjects whose family and/or physician have not committed to aggressive support for 72 hours or who are likely to withdraw within 72 hours.
  • Subjects who are moribund or are not expected to survive hospital discharge due to preexisting uncorrectable medical condition.
  • Subjects who have either Child-Pugh Class B or C cirrhosis.

Treatment and study plan

Sedation,RASS Targeted plus BIS Monitoring

Other

Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring

Sedation, RASS Targeted

Other

Patient sedation utilizing standard of care methods (RASS targeted)

Primary outcomes

  1. Number of ventilator free hours and days

    Time frame: while in ICU, appoximately 3-7 days

Secondary outcomes

  1. Number of delirium and coma free days

    Time frame: while in ICU, appoximately 3-7 days)

  2. Incidence of subacute cognitive dysfunction using RBANS- Repeatable Battery for the Assessment of Neuropsychological Status,

    Time frame: 3 months

  3. Incidence of subacute cognitive dysfunction using TRAILS A&B

    Time frame: 3 months

  4. Incidence of subacute cognitive dysfunction using SF-36 - Short Form Health Survey

    Time frame: 3 months

  5. Incidence of subacute cognitive dysfunction using MMSE - Mini Mental State Examination

    Time frame: 3 months

  6. Incidence of subacute cognitive dysfunction using IADLs - instrumental activities of daily living

    Time frame: 3 months

  7. Incidence of subacute cognitive dysfunction using AD8- ADL - activities of daily living

    Time frame: 3 months

  8. Incidence of subacute cognitive dysfunction using APACHE II - Acute Physiologic and Chronic Health Evaluation II score

    Time frame: 3 months

  9. ICU length of stay

    Time frame: while in ICU, appoximately 3-7 days

  10. Hospital length of stay

    Time frame: while in hospital, usually 5-10 days

  11. Six month mortality

    Time frame: 6 months

  12. Biomarkers for neurological injury and inflammation, Neuron-Specific Enolase (NSE)

    Time frame: Baseline, Day 3 and at Ventilator removal (appoximately day 3-7)

  13. Biomarkers for neurological injury and inflammation, S100

    Time frame: Baseline, Day 3 and at Ventilator removal (appoximately day 3-7)

  14. Biomarkers for neurological injury and inflammation, IL-6

    Time frame: Baseline, Day 3 and at Ventilator removal (appoximately day 3-7)

  15. Biomarkers for neurological injury and inflammation, C Reactive Protein (CRP)

    Time frame: Baseline, Day 3 and at Ventilator removal (appoximately day 3-7)

  16. sleep quality

    Time frame: within 24 hours of enrollment through day 3-7

    measured with continuous polysomnography

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Collaborators

  • Medtronic - MITG

Registry information

Official study title

A Randomized Control Trial Using the BIS Monitor to Avoid Over Sedation and Prolonged Neuropsychological Deficits in Mechanically Ventilated ICU Patients

Acronym: SOMNUS

Important dates

Study start
2007
Primary completion
2008
Study completion
2016
First posted
May 4, 2007
Registry last updated
Mar 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.